Swedish drug-delivery company Nanexa signed a $1.33 billion global licensing deal with Novo Nordisk to use its PharmaShell technology for developing long-acting injectable drugs targeting obesity, type 2 diabetes, and cardiometabolic conditions. Novo Nordisk gains exclusive rights for up to five development programs, aiming for monthly or quarterly drug administration. Nanexa will receive around $700 million upfront, milestone payments, and royalties on future sales, boosting its financial strength and growth potential. The deal caused Nanexa's shares to surge over 135% in early trading in Stockholm.
Novo Nordisk shares trade at USD 38.58 on Pluang as of Sep 25, 2026 17:11 WIB, down 0.10% for the day. The stock shows strong investor interest with 84% buy orders on Pluang. Novo Nordisk's market cap stands at $170.11 billion, reflecting its significant presence in the health sector.
Novo Nordisk revealed a strategy to boost growth beyond its top obesity drugs Wegovy and Ozempic, facing patent expirations in the early 2030s. Despite promising a pipeline of new drugs, investors remain skeptical as Eli Lilly gains market share, esp...
At its Capital Markets Day on September 21, Novo Nordisk announced ambitious plans to launch more than five multi-blockbuster drugs by 2030 and achieve over DKK 150 billion in pipeline sales by 2035. CEO Maziar Doustdar emphasized prioritizing asset ...
Novo Nordisk's CEO Mike Doustdar said the Danish pharma company is open to a direct listing on the New York Stock Exchange, which would replace its current American depositary receipt (ADR) structure. However, the company is not actively pursuing thi...
Viking Therapeutics surged 26.5% after releasing positive topline results from its GLP-1/GIP agonist VK2735 maintenance dosing study in adults with obesity. The data suggest multiple effective maintenance dosing schedules, potentially improving patie...
Novo Nordisk held its investor day in London, outlining its strategy for growth after its key obesity drugs lose patent protection. Despite plans for multiple new blockbusters and expansion into heart and liver disease treatments, analysts were unimp...
